Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.

被引：0
作者：
Hamai, Kosuke
Masuda, Takeshi
Fujitaka, Kazunori
Suzuki, Tomoko
Matsumoto, Naoko
Matsumura, Mirai
Isoyama, Shoko
Ueno, Sayaka
Mito, Mineyo
Yamaguchi, Kakuhiro
Sakamoto, Shinjiro
Kawano, Reo
Masuda, Ken
Nishino, Ryohei
Ishikawa, Nobuhisa
Yamasaki, Masahiro
Hattori, Noboru
机构：
[1] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan
[2] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan
[3] JA Onomichi Gen Hosp, Dept Resp Internal Med, Onomichi, Japan
[4] Hiroshima Red Cross Hosp & Atom Bomb Survivors Ho, Dept Resp Internal Med, Hiroshima, Japan
[5] Kure Med Ctr, Dept Resp Internal Med, Hiroshima, Japan
[6] Hiroshima Univ Hosp, Hiroshima, Japan
[7] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Internal Med, Hiroshima, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21156
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Losanno, Tania
    Gridelli, Cesare
    CURRENT ONCOLOGY REPORTS, 2021, 23 (10)
  • [22] Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer
    Masuda, Takeshi
    Fujitaka, Kazunori
    Ishikawa, Nobuhisa
    Nakano, Kikuo
    Yamasaki, Masahiro
    Kitaguchi, Souichi
    Masuda, Ken
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Kawase, Shigeo
    Miyamoto, Shintaro
    Nakashima, Taku
    Iwamoto, Hiroshi
    Shiota, Naoki
    Senoo, Tadashi
    Awaya, Yoshikazu
    Kondo, Tomohiro
    Yoshida, Takashi
    Hamada, Hironobu
    Murakami, Isao
    Hattori, Noboru
    JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 1079 - 1084
  • [23] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Tania Losanno
    Cesare Gridelli
    Current Oncology Reports, 2021, 23
  • [24] Pembrolizumab mono versus Pembrolizumab plus Chemotherapy as first-line Palliative Therapy for PD-L1-high positive Non-small Cell Lung Cancer: a Two-center Study
    Olive, E.
    Frost, N.
    Grohe, C.
    PNEUMOLOGIE, 2022, 76 : S93 - S93
  • [25] Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
    Shah, Mohsin
    Marmarelis, Melina E.
    Mamtani, Ronac
    Hennessy, Sean
    CLINICAL LUNG CANCER, 2022, 23 (08) : 731 - 736
  • [26] Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Li, Qiu
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 344 - 349
  • [27] Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
    Kenji Morimoto
    Tadaaki Yamada
    Hayato Kawachi
    Motohiro Tamiya
    Yoshiki Negi
    Yasuhiro Goto
    Akira Nakao
    Shinsuke Shiotsu
    Keiko Tanimura
    Takayuki Takeda
    Asuka Okada
    Taishi Harada
    Koji Date
    Yusuke Chihara
    Isao Hasegawa
    Nobuyo Tamiya
    Naoya Nishioka
    Yuki Katayama
    Masahiro Iwasaku
    Shinsaku Tokuda
    Takashi Kijima
    Koichi Takayama
    Targeted Oncology, 2023, 18 : 915 - 925
  • [28] Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).
    Ahn, Myung-Ju
    Barlesi, Fabrice
    Felip, Enriqueta
    Garon, Edward B.
    Martin, Claudio Marcelo
    Mok, Tony S. K.
    Vokes, Everett E.
    Ojalvo, Laureen S.
    Koenig, Andre
    Dussault, Isabelle
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [29] Randomized, Open-Label Study of Bintrafusp Alfa vs. Pembrolizumab as First-Line (1L) Treatment in Patients with PD-L1-Expressing Advanced Non-Small Cell Lung Cancer (NSCLC)
    Ahn, M. -J.
    Barlesi, F.
    Felip, E.
    Garon, E.
    Martin, C. M.
    Vokes, E.
    Koenig, A.
    Dussault, I.
    Ojalvo, L. S.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S27 - S28
  • [30] Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).
    Ahn, Myung-Ju
    Barlesi, Fabrice
    Felip, Enriqueta
    Garon, Edward B.
    Marcelo Martin, Claudio
    Mok, Tony S. K.
    Vokes, Everett E.
    Ojalvo, Laureen S.
    Koenig, Andre
    Dussault, Isabelle
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345